Ticker >

Cipla share price

Cipla Ltd.

NSE: CIPLA BSE: 500087 SECTOR: Pharmaceuticals & Drugs  409k   3k   489

1540.70
+10.85 (0.71%)
BSE: 12 Jun 04:01 PM

Price Summary

Today's High

₹ 1549.35

Today's Low

₹ 1532.45

52 Week High

₹ 1549.55

52 Week Low

₹ 973

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

124414.3 Cr.

Enterprise Value

123447.84 Cr.

No. of Shares

80.75 Cr.

P/E

33.5

P/B

4.45

Face Value

₹ 2

Div. Yield

0.84 %

Book Value (TTM)

₹  346.42

CASH

966.46 Cr.

DEBT

0 Cr.

Promoter Holding

33.47 %

EPS (TTM)

₹  46

Sales Growth

2.66%

ROE

10.49 %

ROCE

14.71%

Profit Growth

-14.33 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Cipla Ltd.

Paracip Montair LC Cipmolnu Dytor Moxicip Novamox Lametec Ibugesic Fourderm CPink CDense Productiv nicotex ActivKids immuno boosters cofsils CIPHANDS OMNIGEL CORYX BRONCOL COUGH SYRUP Cheston

Index Presence

The company is present in 34 Indices.

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year2.66%
3 Year7.65%
5 Year6.75%

Profit Growth

1 Year-15.03%
3 Year2.73%
5 Year11.35%

ROE%

1 Year10.49%
3 Year11.69%
5 Year12.35%

ROCE %

1 Year14.71%
3 Year15.97%
5 Year16.54%

Debt/Equity

0

Price to Cash Flow

40.99

Interest Cover Ratio

128.333086602517

CFO/PAT (5 Yr. Avg.)

1.09925073297861

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2024 33.47 0
Dec 2023 33.47 0
Sep 2023 33.47 0
Jun 2023 33.47 0
Mar 2023 33.55 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 128.333086602517.
  • The Company has been maintaining an effective average operating margins of 21.9829333844765% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of 5.23793159424801 days.
  • Company has a healthy liquidity position with current ratio of 4.95274730159201.
  • The company has a good cash flow management; CFO/PAT stands at 1.09925073297861.

 Limitations

  • The company has shown a poor profit growth of 2.13070779785027% for the Past 3 years.
  • The company has shown a poor revenue growth of 7.64595346249681% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
Net Sales 3565.88 4318.19 4664.72 4381.33 4036.66
Total Expenditure 2854.39 3113.5 3285.6 3025.47 3208.77
Operating Profit 711.49 1204.69 1379.12 1355.86 827.89
Other Income 119.71 157.98 205.09 168.98 538.61
Interest 9.27 0.31 7.8 9.06 5.45
Depreciation 161.58 135.95 179.81 135.02 136.81
Exceptional Items -185.9 0 0 0 0
Profit Before Tax 474.45 1226.41 1396.6 1380.76 1224.24
Tax 184.14 331.39 366.91 363 242.21
Profit After Tax 290.31 895.02 1029.69 1017.76 982.03
Adjusted EPS (Rs) 3.6 11.09 12.75 12.61 12.16

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 12374.01 12659.15 11302.71 15380.82 15790.6
Total Expenditure 9872.01 9972.77 8235.3 11669.59 12005.8
Operating Profit 2502 2686.38 3067.41 3711.23 3784.8
Other Income 577.52 913.76 230.28 666.7 464.57
Interest 16.97 36.05 45.07 26.93 27.02
Depreciation 569.72 599.78 468.62 546.62 595.91
Exceptional Items 0 0 0 0 -185.9
Profit Before Tax 2492.83 2964.31 2784 3804.38 3440.54
Tax 604.42 646.14 739.35 921.8 971.01
Net Profit 1888.41 2318.17 2468.28 2957.93 2513.47
Adjusted EPS (Rs.) 23.44 28.75 25.35 35.73 30.6

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 161.14 161.25 161.29 161.36 161.43
Total Reserves 15620.77 17241.71 19766.27 22352.19 24476.66
Borrowings 0 0 0 0 0
Other N/C liabilities 268.82 383.41 344.24 276.16 258.64
Current liabilities 2368.08 2619.29 2691.94 2632.37 2699.74
Total Liabilities 18418.81 20405.66 22963.74 25449.05 27596.47
Assets
Net Block 4127.46 4024.54 3942.66 3846.57 3747.28
Capital WIP 241.32 255.73 275.04 186.26 441.53
Intangible WIP 56.01 64 80.07 81.42 62.72
Investments 3803.61 6355.32 7720.99 8934.88 9137.91
Loans & Advances 583.23 516.63 596.1 555.68 748.77
Other N/C Assets 130.53 164.72 158.13 509.2 87.13
Current Assets 9476.65 9024.72 10190.75 11335.04 13371.13
Total Assets 18418.81 20405.66 22963.74 25449.05 27596.47
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 2492.83 2964.31 3350.66 3905.08 3685.17
Adjustment 187.6 -35.73 520.41 73.26 269.57
Changes in Assets & Liabilities -761 -245.46 541.19 -270.88 164.57
Tax Paid -451.38 -664.98 -951.95 -934.03 -1084.26
Operating Cash Flow 1468.05 2018.14 3460.31 2773.43 3035.05
Investing Cash Flow -1147.71 -1127.18 -3361.33 -2464.14 -2758.09
Financing Cash Flow -473.32 -693.89 -65.8 -426.72 -424.77
Net Cash Flow -152.98 197.07 33.18 -117.43 -147.81

Corporate Actions

Investors Details

PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
promoters 33.55 33.47 33.47 33.47 33.47
kamil hamied 1.36 1.36 1.36 1.36 1.36
m k hamied - - - - 3.46
okasa pharma private limi... 0.02 0.02 0.02 0.02 0.02
rumana hamied 1.23 1.23 1.23 1.23 1.23
samina hamied 2.23 2.22 2.22 2.22 2.22
shirin hamied 0.79 0.79 0.79 0.79 0.79
sophie ahmed - - - 5.71 5.71
yusuf khwaja hameid - - 18.68 18.68 18.68
m k hamied - - - 3.46 -
mustafa khwaja hamied 3.46 3.46 3.46 - -
sophie ahmed 5.72 5.71 5.71 - -
yusuf khawaja hamied - 18.68 - - -
yusuf khwaja hamied 18.73 - - - -
PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
investors 66.45 66.53 66.53 66.53 66.53
government pension fund g... 2.91 2.96 2.75 2.91 2.36
hdfc mutual fund 2.65 3.19 3.60 - 4.47
investor education and pr... 0.32 - 0.32 0.33 0.33
lic 2.15 3.47 2.88 3.46 3.67
nps trust 1.80 1.98 1.91 - 1.66
sbi mutual fund 4.51 4.53 4.68 - 4.23
hdfc trustee company ltd.... - - - 4.32 -
icici prudential nifty50 ... - - - 1.02 -
nps trust - - - 1.73 -
sbi arbitrage opportuniti... - - - 4.68 -
uti balanced advantage fu... - - - 1.12 -
government of singapore 1.12 1.13 1.02 - -
icici prudential mutual f... - - 1.06 - -
kotak mutual fund - - 1.07 - -
uti 1.09 1.22 1.14 - -
investor education and pr... - 0.32 - - -
gqg partners emerging mar... 1.20 - - - -
icici prudential fund 1.07 - - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Cipla informs about disclosure22 May 2024, 12:56PM Cipla gets USFDA’s final nod for Lanreotide injection22 May 2024, 11:42AM Cipla inks pact to make additional investment in Achira Labs 16 May 2024, 10:58AM Cipla’s promoters sell 2.53% stake in company15 May 2024, 4:59PM Cipla informs about clarification15 May 2024, 11:06AM Cipla reports 79% rise in Q4 consolidated net profit10 May 2024, 3:26PM Cipla - Quaterly Results10 May 2024, 2:30PM Cipla - Quaterly Results10 May 2024, 2:30PM Cipla - Quaterly Results10 May 2024, 2:30PM Cipla's arm acquires business undertaking from Ivia Beaute29 Apr 2024, 10:30AM Cipla informs about allotment of equity shares 16 Apr 2024, 2:48PM Cipla's arm signs agreement for acquisition of business undertaking from Ivia Beaute16 Apr 2024, 9:20AM USFDA concludes routine cGMP inspection at Cipla’s manufacturing facility in Patalganga 5 Apr 2024, 9:24AM Cipla partners with Sanofi India27 Mar 2024, 10:46AM Cipla’s arm completes sale of entire shareholding in Wellthy7 Mar 2024, 9:25AM Cipla transfers Generics Business Undertaking to Cipla Pharma and Life Sciences2 Mar 2024, 9:33AM Cipla secures approval to market novel antibiotic plazomicin in India27 Feb 2024, 4:57PM Cipla ties up with CSIR-CDRI16 Feb 2024, 10:41AM Cipla’s arm completes acquisition of 100% equity stake in Actor Pharma8 Feb 2024, 9:20AM Cipla acquires additional stake in GoApptiv3 Feb 2024, 10:25AM Cipla’s arms incorporate wholly owned subsidiary in Mexico23 Jan 2024, 3:12PM Cipla reports 32% rise in Q3 consolidated net profit23 Jan 2024, 2:26PM Cipla - Quaterly Results22 Jan 2024, 6:49PM Cipla - Quaterly Results22 Jan 2024, 6:49PM Cipla informs about acquisition6 Jan 2024, 12:44PM Cipla’s arm to incorporate JV Company in USA6 Jan 2024, 10:53AM Cipla informs about revised press release16 Dec 2023, 2:22PM Cipla to further invest Rs 42 crore in GoApptiv15 Dec 2023, 12:30PM Cipla's arm recalls one lot of Vigabatrin for oral solution USP 500 mg11 Dec 2023, 9:50AM Cipla’s arm acquires additional 15.10% stake in Cipla Maroc SA28 Nov 2023, 11:53AM Cipla’s Pithampur manufacturing facility gets warning letter from USFDA20 Nov 2023, 9:49AM Cipla executes facility demand guarantee for extending general banking facilities18 Nov 2023, 3:29PM Cipla informs about disclosure 18 Nov 2023, 12:49PM Cipla’s arms complete sale of entire 51.18% stake in CQCIL15 Nov 2023, 3:29PM Cipla gets nod to transfer generics business undertaking6 Nov 2023, 5:21PM Cipla reports 45% rise in Q2 consolidated net profit27 Oct 2023, 2:30PM Cipla - Quaterly Results27 Oct 2023, 1:46PM Cipla - Quaterly Results27 Oct 2023, 1:46PM Cipla - Quaterly Results27 Oct 2023, 1:46PM Cipla informs about conference call7 Oct 2023, 1:17PM Cipla divests 51% stake in Saba Investment, UAE30 Sep 2023, 10:16AM Cipla launches drone-powered critical medicine delivery in Himachal Pradesh27 Sep 2023, 11:30AM USFDA issues 5 inspectional observations to New York facility of Cipla’s arm21 Sep 2023, 10:23AM Cipla’s arm to acquire 100% stake in Actor Pharma5 Sep 2023, 9:39AM Cipla’s associate company incorporates wholly owned subsidiary27 Jul 2023, 9:49AM Cipla informs about unaudited financial results 26 Jul 2023, 4:51PM Cipla reports 41% rise in Q1 consolidated net profit26 Jul 2023, 3:51PM Cipla - Quaterly Results26 Jul 2023, 3:16PM Cipla - Quaterly Results26 Jul 2023, 3:16PM Cipla - Quaterly Results26 Jul 2023, 3:16PM

Cipla Stock Price Analysis and Quick Research Report. Is Cipla an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Cipla and its performance over the period of time. Cipla stock price today is Rs 1540.95.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Cipla cash from the operating activity was Rs 3035.05 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Cipla has a Debt to Equity ratio of 0 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Cipla , the EPS growth was -14.3663619621256 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Cipla has OPM of 23.96869023343 % which is a good sign for profitability.
     
  • ROE: Cipla have a average ROE of 10.4917421284744 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Cipla is Rs 1540.95. One can use valuation calculators of ticker to know if Cipla share price is undervalued or overvalued.
Last Updated on:
Brief about Cipla

Cipla Ltd. Financials: Check Share Price, Balance Sheet, Annual Report and Quarterly Results for Company Analysis

Cipla Ltd. is a leading Indian pharmaceutical company that operates in the global market. In this article, we will provide a comprehensive analysis of Cipla's stock from a long-term investor's perspective. We will cover various topics such as share price, balance sheet, annual report, dividend, quarterly result, stock price, price chart, news, concall, transcripts, investor presentations, promoters, and shareholders.

Cipla Ltd. Share Price:

Cipla's share price is a crucial indicator of investor sentiment towards the company. The share price is influenced by various factors such as the company's financial performance, global economic conditions, and market sentiment. Long-term investors can use our pre-built screening tools to analyze Cipla's share price and identify any trends or patterns. The company's share price has shown a steady upward trend over the past few years, reflecting the company's strong financial performance and growth prospects.

Cipla Ltd. Balance Sheet:

Cipla's balance sheet provides crucial information about its financial health. The company's assets include research and development facilities, manufacturing facilities, and other fixed assets, while liabilities include borrowings and other liabilities. Equity includes share capital, reserves, and surplus. Long-term investors can use our pre-built screening tools to analyze Cipla's balance sheet and identify any red flags. The company's balance sheet has remained strong over the past few years, reflecting the company's low debt levels and strong operating cash flows.

Cipla Ltd. Annual Report:

Cipla releases an annual report every year, which provides detailed information about the company's financial performance, strategic initiatives, and future plans. The annual report includes a letter from the Chairman, financial statements, and management discussion and analysis. Long-term investors can download Cipla's annual report from our website and use it to make informed investment decisions. The annual report provides valuable insights into the company's operations and financial performance.

Cipla Ltd. Dividend:

Cipla has a consistent dividend history. The company has paid dividends every year, reflecting its commitment to rewarding shareholders. Long-term investors should consider this when evaluating Cipla's stock. Our pre-built screening tools can be used to analyze the company's dividend history and identify any trends or patterns.

Cipla Ltd. Quarterly Results:

Cipla releases its quarterly results every three months. The quarterly results provide information about the company's revenue, earnings, and expenses. Long-term investors can use our pre-built screening tools to analyze Cipla's quarterly results and identify any trends or patterns. The quarterly results are an important indicator of the company's financial health and performance.

Cipla Ltd. Stock Price:

The stock price of Cipla is affected by various factors such as the company's financial performance, global economic conditions, and market sentiment. Long-term investors can use our pre-built screening tools to track Cipla's stock price and identify potential buying opportunities. The stock price of Cipla has shown a steady upward trend over the past few years, reflecting the company's strong financial performance and growth prospects.

Cipla Ltd. Price Chart:

A price chart provides a visual representation of a company's stock price over a period of time. Long-term investors can use our pre-built screening tools to analyze Cipla's price chart and identify any trends or patterns. The price chart shows that the stock price of Cipla has shown a steady upward trend over the past few years, reflecting the company's strong financial performance and growth prospects.

Cipla Ltd. News:

Keeping up to date with the latest news about Cipla is important for investors. Our website provides the latest news about Cipla from various sources such as financial news websites and social media. Long-term investors can use this information to make informed investment decisions.

Cipla Ltd. Concall:

Cipla holds conference calls with analysts and investors to discuss its financial performance and future plans. Long-term investors can listen to Cipla's concall and use the information provided to make informed investment decisions. Our website provides information about upcoming concalls and links to listen to past concalls.

Cipla Ltd. Transcripts:

Transcripts of Cipla's concalls are available on our website. Long-term investors can download the transcripts and use them to analyze the company's financial performance and future plans. The transcripts provide valuable insights into the company's operations and financial performance.

Cipla Ltd. Investor Presentations:

Cipla provides investor presentations on its website. These presentations provide information about the company's financial performance, strategic initiatives, and future plans. Long-term investors can download Cipla's investor presentations from our website and use them to make informed investment decisions. The investor presentations provide valuable insights into the company's operations and financial performance.

Cipla Ltd. Promoters:

Promoters are individuals or entities that have a significant stake in a company. Cipla's promoters include the founding family and institutional investors. Long-term investors can use our pre-built screening tools to analyze Cipla's promoter holdings and identify any potential conflicts of interest. The promoter holdings of Cipla are relatively stable, which is a positive sign for long-term investors.

Cipla Ltd. Shareholders:

Cipla has a large number of shareholders, including institutional investors and individual investors. Long-term investors can use our pre-built screening tools to analyze Cipla's shareholder base and identify any potential risks or opportunities. The shareholder base of Cipla is diverse, which is a positive sign for long-term investors.

Cipla Ltd. Premium Features:

Our website provides premium features tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis. These tools can help long-term investors make better investment decisions by providing more detailed insights into the company's financial performance and valuation.

Cipla Limited ROCE

Cipla Limited ROCE (Return on Capital Employed) represents the company's ability to generate profits from the capital invested in its business. This ratio considers both equity and debt in the calculation and helps an investor evaluate the efficiency of a company's investment in its operations. You can get the ROCE data for Cipla Limited on this stock analysis page in the financials table or ratio section.

Cipla Limited EBITDA

Cipla Limited EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is a profitability metric that measures the company's operating performance. It reflects cash flow generated from the business operations, excluding non-operating expenses such as interest, taxes, depreciation, and amortization. Investors can use EBITDA as a metric to compare companies that operate in the same industry. You can find the EBITDA data for Cipla Limited on this stock analysis page within the financials or ratio section.

Cipla Limited DPS

Cipla Limited DPS (Dividend Per Share) is a metric that indicates the amount of dividend a company pays to its shareholders per share of stock they own. A consistently high DPS indicates a financially stable company that is returning value to its shareholders. Additionally, changes in DPS can provide insights into the company's financial status and future growth prospects. You can access the DPS data for Cipla Limited on this stock analysis page in the financials or ratio section.

Cipla Limited EPS

Cipla Limited EPS (Earnings Per Share) is a metric that indicates the amount of profit generated by the company per share of outstanding common stock. It provides insights into the company's profitability on a per-share basis and can help investors evaluate a company's growth potential. A high EPS usually indicates a fundamentally sound company with a strong financial position. This stock analysis page provides data on Cipla Limited's EPS within the financials or ratio section.

Read More
X